Methoxyacetylfentanyl

Methoxyacetylfentanyl, commonly known as MAF is an opioid analgesic that is an analog of fentanyl and has been sold online as a designer drug.[1]

Methoxyacetylfentanyl
Legal status
Legal status
  • CA: Schedule I
  • DE: Anlage II (Authorized trade only, not prescriptible)
  • UK: Class A
  • US: Schedule I
Identifiers
IUPAC name
  • 2-Methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC22H28N2O2
Molar mass352.47 g·mol−1
3D model (JSmol)
SMILES
  • c3ccccc3N(C(=O)COC)C1CCN(CC1)CCc2ccccc2
InChI
  • InChI=1S/C22H28N2O2/c1-26-18-22(25)24(20-10-6-3-7-11-20)21-13-16-23(17-14-21)15-12-19-8-4-2-5-9-19/h2-11,21H,12-18H2,1H3
  • Key:SADNVKRDSWWFTK-UHFFFAOYSA-N

Side effects

Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.[2] A new wave of fentanyl analogues and associated deaths began in around 2014 in the US, and have continued to grow in prevalence; especially since 2016 these drugs have been responsible for hundreds of overdose deaths every week.[3]

Methoxyacetylfentanyl was placed into Schedule I in the US in October 2017, in order to avoid an imminent hazard to public safety.[4]

See also

References
  1. European Monitoring Centre for Drugs Drug Addiction; European Union Agency for Law Enforcement Cooperation (February 2017). Methoxyacetylfentanyl : EMCDDA–Europol joint report on a new psychoactive substance : 2-methoxy-N-phenyl-N-1-(2-phenylethyl)piperidin-4-ylacetamide (methoxyacetylfentanyl) : in accordance with Article 5 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. Publications Office. doi:10.2810/786704. ISBN 9789294972569.
  2. Mounteney J, Giraudon I, Denissov G, Griffiths P (July 2015). "Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe". The International Journal on Drug Policy. 26 (7): 626–31. doi:10.1016/j.drugpo.2015.04.003. PMID 25976511.
  3. Armenian P, Vo KT, Barr-Walker J, Lynch KL (October 2017). "Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review" (PDF). Neuropharmacology. 134 (Pt A): 121–132. doi:10.1016/j.neuropharm.2017.10.016. PMID 29042317. S2CID 21404877.
  4. Drug Enforcement Administration, Department of Justice (October 2017). "Schedules of Controlled Substances: Temporary Placement of ortho-Fluorofentanyl, Tetrahydrofuranyl Fentanyl, and Methoxyacetyl Fentanyl Into Schedule I. Temporary amendment; temporary scheduling order" (PDF). Federal Register. 82 (206): 49504–8. PMID 29091366.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.